11 news items
HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
EVAX
4 Jun 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14 price target.
Evaxion Presents Validating Immune Data From Ongoing Phase 2 Trial With AI-Designed EVX-01 Vaccine At The ASCO Annual Meeting 2024
EVAX
3 Jun 24
Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients
Evaxion Announces Business Update and First Quarter 2024 Financial Results
EVAX
28 May 24
focusing on Targets, Pipeline, and Responders with a multi-partner approach. Key highlights include
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
EVAX
23 May 24
precisely select vaccine targets and design personalized vaccines that match each patient's unique tumor signature and immune characteristics. This represents
Evaxion Receives Nasdaq Notification
EVAX
10 May 24
in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients' lives by providing innovative and targeted
x16izsuc88ykxp9sapkdgzlm0ddyl315qcgn3dlu5v6 vn
EVAX
17 Apr 24
needs. Evaxion is committed to transforming patients' lives by providing innovative and targeted treatment options. For more information about
77183kwsmkv ecy
EVAX
3 Apr 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14 price target.
553g9 8wsqo4fjtbwmainh7trn4risggi6hbk
EVAX
2 Apr 24
Ladenburg Thalmann analyst Ahu Demir upgrades Evaxion Biotech (NASDAQ:EVAX) from Neutral to Buy and announces $8 price target.
tou sgahqj0gfnk6ty3pzadr
EVAX
2 Apr 24
is committed to transforming patients' lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking
yx599rsuqs03dt0a6k9kdmsrnotg4phfnzg2rfm9yrhdgqoxxxxftd
EVAX
27 Mar 24
class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines
6uf1akk5vnlexfl3aeqz6tnj23bca3gbnqx0t4dvd45gfo
EVAX
19 Mar 24
and machine learning technologiesAI-Immunology™ outcompetes standard vaccine target discovery approaches
- Prev
- 1
- Next